Interpace Biosciences, Inc. (IDXGD)
OTCMKTS · Delayed Price · Currency is USD
6.91
+0.40 (6.18%)
At close: Sep 4, 2026
Interpace Biosciences Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 38 | 5 | 12 | 5 | 4 | 31 | |
Market Cap Growth | 995.99% | -54.11% | 152.98% | 5.76% | -85.77% | 145.72% |
Enterprise Value | 37 | 6 | 63 | 60 | 58 | 87 |
Last Close Price | 6.91 | 6.15 | 13.49 | 5.40 | 5.20 | 37.35 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 1.52 | 0.22 | 1.90 | 2.40 | - | - |
Forward PE | - | 111.43 | 111.43 | 111.43 | 111.43 | 111.43 |
PS Ratio | 1.06 | 0.14 | 0.25 | 0.12 | 0.14 | 0.94 |
PB Ratio | 1.65 | 0.24 | -5.35 | -0.52 | -0.27 | 7.57 |
P/TBV Ratio | 1.65 | 0.24 | - | - | - | - |
P/FCF Ratio | 9.33 | 1.00 | 3.15 | 1.41 | - | - |
P/OCF Ratio | 8.59 | 0.93 | 2.56 | 1.24 | - | - |
PEG Ratio | - | 48.93 | 48.93 | 48.93 | 48.93 | 48.93 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.01 | 0.16 | 1.35 | 1.49 | 1.82 | 2.62 |
EV/EBITDA Ratio | 7.04 | 1.21 | 7.55 | 11.97 | - | - |
EV/EBIT Ratio | 8.76 | 1.31 | 7.83 | 15.07 | - | - |
EV/FCF Ratio | 8.91 | 1.15 | 16.84 | 18.00 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.04 | 0.05 | -2.64 | -1.24 | -0.97 | 2.60 |
Debt / EBITDA Ratio | 0.19 | 0.20 | 0.64 | 1.93 | - | 34.59 |
Debt / FCF Ratio | 0.24 | 0.22 | 1.55 | 3.37 | - | - |
Net Debt / Equity Ratio | -0.07 | -0.06 | -1.98 | -0.85 | -0.68 | 1.96 |
Net Debt / EBITDA Ratio | -0.37 | -0.25 | 0.52 | 1.54 | -8.80 | -20.65 |
Net Debt / FCF Ratio | -0.42 | -0.24 | 1.17 | 2.32 | -1.40 | -0.89 |
Asset Turnover | 1.54 | 1.59 | 3.36 | 2.75 | 1.17 | 0.79 |
Inventory Turnover | 12.73 | 12.56 | 13.95 | 12.22 | 13.28 | 9.95 |
Quick Ratio | 1.82 | 1.60 | 0.94 | 0.75 | 0.69 | 0.47 |
Current Ratio | 2.22 | 1.94 | 1.11 | 0.91 | 0.85 | 0.78 |
Return on Equity (ROE) | 225.68% | 248.03% | - | - | - | -65.25% |
Return on Assets (ROA) | 11.13% | 12.30% | 36.32% | 17.03% | -8.82% | -8.57% |
Return on Invested Capital (ROIC) | 19.40% | 37.94% | 276.70% | 233.03% | -55.39% | -36.49% |
Return on Capital Employed (ROCE) | 14.10% | 16.60% | 194.10% | 235.90% | -226.40% | -25.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 63.84% | 451.08% | 56.45% | 41.64% | -494.86% | -47.92% |
FCF Yield | 10.72% | 100.50% | 31.75% | 70.72% | -180.61% | -29.10% |
Buyback Yield / Dilution | -0.30% | -76.02% | -260.54% | -2.97% | -2.49% | -2.63% |